Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study

Salehzadeh et al., Mediterranean Journal of Rheumatology, doi:10.31138/mjr.33.2.232 (date from preprint), IRCT20200418047126N1
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Hospitalization time 23% Improvement Relative Risk Colchicine  Salehzadeh et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 100 patients in Iran (May - June 2020) Shorter hospitalization with colchicine (p=0.001) c19early.org Salehzadeh et al., Mediterranean J. Rh.., Sep 2020 Favors colchicine Favors control
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Open label RCT with 100 hospitalized patients in Iran, 50 treated with colchicine, showing shorter hospitalization time with treatment. There were no deaths.
hospitalization time, 22.7% lower, relative time 0.77, p = 0.001, treatment 50, control 50.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Salehzadeh et al., 21 Sep 2020, Randomized Controlled Trial, Iran, peer-reviewed, median age 56.0, 3 authors, study period 21 May, 2020 - 20 June, 2020, average treatment delay 6.28 (treatment) 8.12 (control) days, trial IRCT20200418047126N1. Contact: sobhan13295@gmail.com.
This PaperColchicineAll
The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study
Farhad Salehzadeh, Farhad Pourfarzi, MD Sobhan Ataei
Mediterranean Journal of Rheumatology, doi:10.31138/mjr.33.2.232
Acute respiratory distress syndrome COVID-19: Coronavirus Disease 2019 ICU: Intensive care unit IL: Interleukin BACKGROUND In late 2019, several cases of an acute respiratory illness (now known as the new coronavirus or COVID-19) were reported in Wuhan, China. [1] [2] [3] The coronavirus has spread rapidly to all over the world. As of Dec. 1, 2020, a total of over 61.8 million people infected by the virus and caused 1.4 million deaths all over the world. 4 There are various reports on the pathophysiology of the disease. Many studies have suggested that an overreaction of the immune system by virus ©Salehzadeh F, Pourfarzi F, Ataei S.
Custom Trial registration ID is: 47707 (irct.ir). The written confirmed consent obtained from all participants. Current Controlled prospective Trials registration ID that has been approved by ICMJE and WHO ICTRP registry is IRCT20200418047126N1, and the date of registration is 2020-05-14. CONSENT FOR PUBLICATION Authors have taken written informed consent for this work. CONFLICT OF INTEREST The authors declare no conflict of interest. FUNDING Authors declare no private funding in this study. AUTHOR CONTRIBUTIONS All authors have read and approved the manuscript and they contribute as: FP, Worked on epidemiologic aspects of the study; FS designed the study and wrote draft copy, SA collected all data and wrote the final copy.
References
Buonaguro, Puzanov, Ascierto, Anti-IL6R role in treatment of COVID-19-related ARDS, J Transl Med
Cascella, Rajnik, Cuomo, Dulebohn, Napoli, Features, Evaluation and Treatment Coronavirus (COVID-19)
Chen, Xiong, Bao, Shi, Convalescent plasma as a potential therapy for COVID-19, Lancet Infect Dis
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open
Gautret, Lagier, Parola, Hoang Thuan, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Hui, Azhar, Madani, Ntoumi, Kock et al., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: the latest 2019 novel corona cytokine virus outbreak in Wuhan
Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle
Mansouri, Marjani, Tabarsi, Garnier, Mansouri, Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature, Immunological Investigations, Immunol Invest
Martínez, Robertson, Barraclough, Xia, Mallat et al., Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome, J Am Heart Assoc
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Robertson, Martínez, Payet, Barraclough, Celermajer et al., Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation, Clin Sci (Lond)
Slobodnick, Shah, Krasnokutsky, Pillinger, Update on colchicine, Rheumatology
Tanaka, Narazaki, Kishimoto, Immunotherapeutic implications of IL-6 blockade for cytokine storm, Immunotherapy
Tisoncik, Korth, Simmons, Farrar, Martin et al., None, Microbiol Mol Biol Rev Mar
Vardhana, Wolchok, The many faces of the anti-COVID immune response, J Exp Med
Vitiello, Ferrara, Pelliccia, Granata, Porta, Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia, Ital J Med
Zhang, Wu, Li, Zhao, Wang, The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents
{ 'indexed': {'date-parts': [[2022, 9, 6]], 'date-time': '2022-09-06T16:42:58Z', 'timestamp': 1662482578742}, 'reference-count': 0, 'publisher': 'Convin SA', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022]]}, 'DOI': '10.31138/mjr.33.2.232', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 6]], 'date-time': '2022-09-06T15:36:34Z', 'timestamp': 1662478594000}, 'page': '232', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study', 'prefix': '10.31138', 'volume': '33', 'author': [ { 'given': 'Farhad', 'family': 'Salehzadeh', 'sequence': 'first', 'affiliation': [ { 'name': 'Pediatric Department, Bouali Children`s Hospital, Ardabil ' 'University of Medical Sciences (ARUMS), Ardabil, Iran,'}]}, { 'given': 'Farhad', 'family': 'Pourfarzi', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Community Medicine, Ardabil University of Medical ' 'Sciences (ARUMS), Ardabil, Iran,'}]}, { 'given': 'Sobhan', 'family': 'Ataei', 'sequence': 'first', 'affiliation': [ { 'name': 'Pediatric Department, Bouali Children’s Hospital, Ardabil ' 'University of Medical Sciences (ARUMS), Ardabil, Iran'}]}], 'member': '16240', 'container-title': 'Mediterranean Journal of Rheumatology', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2022, 9, 6]], 'date-time': '2022-09-06T15:59:00Z', 'timestamp': 1662479940000}, 'score': 1, 'resource': {'primary': {'URL': 'http://www.mjrheum.org/assets/files/792/file382_1566.pdf'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022]]}, 'references-count': 0, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022, 6]]}}, 'alternative-id': ['file382_1566'], 'URL': 'http://dx.doi.org/10.31138/mjr.33.2.232', 'relation': {}, 'ISSN': ['2529-198X'], 'subject': ['Rheumatology'], 'container-title-short': 'MJR', 'published': {'date-parts': [[2022]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit